Intervention not reported
Death within 5 years · patients with early‐stage cervical cancer (FIGO stages IB1, IB2 or IIA)
The intervention showed no clear difference in death within 5 years (moderate certainty).
1 finding from 1 review
Intervention not reported
Disease progression within 5 years · patients with early‐stage cervical cancer (FIGO stages IB1, IB2 or IIA)
The intervention probably leads to lower disease progression within 5 years (moderate certainty).
1 finding from 1 review
Intervention not reported
Haematological adverse events (grade 3 or 4) · patients with early‐stage cervical cancer (FIGO stages IB1, IB2 or IIA)
The intervention showed no clear difference in haematological adverse events (grade 3 or 4) (moderate certainty).
1 finding from 1 review
Intervention not reported
Gastrointestinal adverse events (grade 3 or 4) · patients with early‐stage cervical cancer (FIGO stages IB1, IB2 or IIA)
The intervention showed no clear difference in gastrointestinal adverse events (grade 3 or 4) (moderate certainty).
1 finding from 1 review
Intervention not reported
Genitourinary adverse events (grade 3 or 4) · patients with early‐stage cervical cancer (FIGO stages IB1, IB2 or IIA)
The intervention showed no clear difference in genitourinary adverse events (grade 3 or 4) (moderate certainty).
1 finding from 1 review
Intervention not reported
Pain ‐ not measured · patients with chronic (>12 months) lateral elbow pain
The review found no eligible studies for this question.
1 finding from 1 review
Intervention not reported
Adverse events ‐ not measured · patients with chronic (mean 23 months) lateral elbow pain
The review found no eligible studies for this question.
1 finding from 1 review
Intervention not reported
Pain ‐ not reported · patients with chronic (>6 months) lateral elbow pain
The review found no eligible studies for this question.
1 finding from 1 review
Intervention not reported
Disabilty ‐ not measured · patients with chronic (>6 months) lateral elbow pain
The review found no eligible studies for this question.
1 finding from 1 review
Intervention not reported
Adverse events ‐ not measured · patients with chronic (>6 months) lateral elbow pain
The review found no eligible studies for this question.
1 finding from 1 review
Intervention not reported
Disability DASH scale. Scale from: 0 to 100. ( · patients with chronic (>12 months) lateral elbow pain
1 finding from 1 review
Intervention not reported
Adverse events ‐ not measured · patients with chronic (>12 months) lateral elbow pain
The review found no eligible studies for this question.
1 finding from 1 review
Intervention not reported
Pain‐ short term VAS scale. Scale from: 0 to 10. ( · patients with lateral elbow pain
1 finding from 1 review
Intervention not reported
Pain‐ long term VAS. Scale from: 0 to 10. ( · patients with lateral elbow pain
1 finding from 1 review
Intervention not reported
Disability Mayo Elbow Performance. Scale from: 0 to 100. ( · patients with lateral elbow pain
1 finding from 1 review
Intervention not reported
Adverse events ‐ not reported · patients with lateral elbow pain
The review found no eligible studies for this question.
1 finding from 1 review
Intervention not reported
Pain ‐ not reported · patients with chronic (mean 23 months) lateral elbow pain
The review found no eligible studies for this question.
1 finding from 1 review
Intervention not reported
Disability ‐ not measured · patients with chronic (mean 23 months) lateral elbow pain
The review found no eligible studies for this question.
1 finding from 1 review
Pain Visual analog scale Scale from 0 to 100 (lower is better) · patients with Shoulder osteoarthritis
1 finding from 1 review
Disability/Function (ASES) American Shoulder and Elbow Surgeons Shoulder Score. Scale from: 0 to 100 (Higher is better). · patients with Shoulder osteoarthritis
1 finding from 1 review